Insider Selling: Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Sells 5,931 Shares of Stock

Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Valerie Morisset sold 5,931 shares of Eliem Therapeutics stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $6.66, for a total value of $39,500.46. Following the transaction, the executive vice president now directly owns 444,683 shares of the company’s stock, valued at $2,961,588.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Valerie Morisset also recently made the following trade(s):

• On Thursday, July 11th, Valerie Morisset sold 50,000 shares of Eliem Therapeutics stock. The stock was sold at an average price of $7.11, for a total transaction of $355,500.00.
• On Friday, July 5th, Valerie Morisset sold 12,342 shares of Eliem Therapeutics stock. The shares were sold at an average price of $7.06, for a total transaction of $87,134.52.
• On Wednesday, July 3rd, Valerie Morisset sold 50,000 shares of Eliem Therapeutics stock. The stock was sold at an average price of $6.76, for a total transaction of $338,000.00.

Eliem Therapeutics Price Performance

Shares of ELYM traded down $0.10 on Thursday, hitting $7.07. The company’s stock had a trading volume of 126,062 shares, compared to its average volume of 469,389. The company has a market capitalization of $210.33 million, a PE ratio of -13.34 and a beta of -0.33. Eliem Therapeutics, Inc. has a fifty-two week low of $2.35 and a fifty-two week high of $11.55. The company has a 50 day moving average price of $7.93 and a 200 day moving average price of $4.78.

Eliem Therapeutics (NASDAQ:ELYM) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.06) EPS for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Eliem Therapeutics stock. Cerity Partners LLC bought a new position in Eliem Therapeutics, Inc. (NASDAQ:ELYM) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 13,821 shares of the company’s stock, valued at approximately $37,000. Cerity Partners LLC owned about 0.05% of Eliem Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 69.76% of the company’s stock.

About Eliem Therapeutics

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.